

Pharmacy Formulary Updates for November 2024

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in November 2024:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Abrilada	NF;SPP;QL
Acthar	T3;PA;SPP
Amjevita	NF;SPP;QL
Clobetasol Propionate Ophth Susp 0.05%	NF
Crexont	NF
Cyltezo	NF;SPP;QL
Entresto Sprinkle	T2;QL
Glimepiride 3 mg	NF
Hadlima	NF;SPP;QL
Hulio	NF;SPP;QL
Hyrimoz	NF;SPP;QL
Idacio	NF;SPP;QL
Ohtuvayre	T3;PA
Simlandi	NF;SPP;QL
Sofdra	NF;QL
Tryvio	NF
Vigafyde	NF
Yuflyma	NF;SPP;QL
Yusimry	NF;SPP;QL
Zoryve 0.15%	T3;PA